HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

Altimmune, Inc.

1
Articles
Mentioned
Top Role
Feb 18, 2026
First Mention
Feb 18, 2026
Last Mention
0.61
Relevance Score

Coverage Timeline

February 2026
Late-Stage Obesity Drugs Beyond GLP-1s: Orforglipron, Survodutide, and the Oral Alternatives That Could Reshape Pricing Pipeline Mentioned
Feb 18, 2026
The late-stage field is crowded: Altimmune’s pemvidutide, Pfizer’s danuglipron, other oral peptide mimetics, trials are everywhere.
Related Companies
Boehringer Ingelheim GmbH
1 shared
Novo Nordisk A/S
1 shared
Eli Lilly and Company
1 shared
Pfizer Inc.
1 shared